Advertisement
Canada markets close in 5 hours 26 minutes
  • S&P/TSX

    21,508.35
    -189.76 (-0.87%)
     
  • S&P 500

    5,409.77
    -23.97 (-0.44%)
     
  • DOW

    38,351.08
    -296.02 (-0.77%)
     
  • CAD/USD

    0.7262
    -0.0017 (-0.24%)
     
  • CRUDE OIL

    78.51
    -0.11 (-0.14%)
     
  • Bitcoin CAD

    91,685.31
    -1,064.94 (-1.15%)
     
  • CMC Crypto 200

    1,423.47
    +5.59 (+0.39%)
     
  • GOLD FUTURES

    2,348.80
    +30.80 (+1.33%)
     
  • RUSSELL 2000

    2,004.01
    -34.90 (-1.71%)
     
  • 10-Yr Bond

    4.2070
    -0.0310 (-0.73%)
     
  • NASDAQ

    17,646.12
    -21.44 (-0.12%)
     
  • VOLATILITY

    12.73
    +0.79 (+6.62%)
     
  • FTSE

    8,141.80
    -21.87 (-0.27%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • CAD/EUR

    0.6798
    +0.0024 (+0.35%)
     

ADC Therapeutics First Quarter 2024 Earnings: In Line With Expectations

ADC Therapeutics (NYSE:ADCT) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$18.1m (down 4.9% from 1Q 2023).

  • Net loss: US$46.6m (loss narrowed by 22% from 1Q 2023).

  • US$0.56 loss per share (improved from US$0.73 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

ADC Therapeutics Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are down 3.4% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 4 warning signs for ADC Therapeutics (1 is potentially serious!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.